Method of producing crystalline form of monoethanolamine salt of n-(2-pyridyl)-2-methyl-4-oxy-2n-1,2

专利摘要:
A novel crystalline form of the monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide has been prepared. This novel crystalline form is designated as polymorph I and is useful in therapy as a nonsteroidal antiarthritic agent. Methods for preparing this polymorph from readily available materials are provided.
公开号:SU1491339A3
申请号:SU853982430
申请日:1985-11-15
公开日:1989-06-30
发明作者:Ли Робертсон Роберт
申请人:Пфайзер Инк (Фирма)；
IPC主号:

专利说明:

The invention relates to a novel crystalline form of the monoetinolamine salt of H- (2-pyridyl) -2-methyl-4- -OXI-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide-polymorph I, which It can be used in therapy as a non-steroid drug for the treatment of inflammatory processes due to the unique combination of its physical, chemical and biological properties.
The aim of the invention is to obtain a crystalline polymorphic form of the monoethanolamine salt of H- (2-pyridyl) -2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, having a higher storage stability.
Example. Under the conditions of absolute purity, 550 g (1.66 mol) of N- (2-pyridyl) -2-methyl-4-OXY-2H-1,2-benzothiazine-3-carboxyside 1, 1-dioxide is dissolved in 6.6 l of chlorine and methylene at 25-30 ° C. The resulting solution is filtered through a fluted filter paper into a clean 12-liter three-necked round-bottom flask equipped with a stirrer and purged with nitrogen. The solution is stirred and 1.0 g of the monoethanolamine salt of the N- (2-pyridyl) -2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide is added to it as a seed. Then pacTBof of 106.7 g (1.75 mol) of monostaminolamine in 1.1 l of methylene chloride is added to the mixture over 1 hour. The mixture is then granulated at ambient temperature for 3 hours and then filtered. The filtered crystals are washed on a funnel with a filter (i.e. a filter in several layers) in three portions of 1000 MP of methylene chloride at 23 ° C, then dried in a vacuum oven for about 16 hours. Thus, 643.1 g are obtained. pure crystalline monoethanolamine salt of N- (2-pyridyl) -2-methyl-4-ox-SI-2I-1,2-benzothiazine-3-carboxamide 1,1-dioxide, etc. 170-173 ° C. The net yield (642.1 g) is 98.6% of the theoretical. After grinding, the product has a mass of 621 g, then it is again dried in a vacuum oven at 35-38 ° C for 20 hours. The final m.p. 172-173 C. This product is named polymorph II.
Example 2. A sample of monoethanolamine salt of N- (2-pyridyl) -2-me-TSH1-4-OXI-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide mass of 20 g, obtained in accordance with example 1 (polymorph II), dissolved in 400 MP of anhydrous ethanol at a temperature of deglebmal and. The resulting clear solution is then filtered through a fluted filter paper into a clean 500 ml Erlenmeyer flask. The filtered solution is then stirred with a magnetic stirrer at ambient temperature for 3.3 hours (temperature 25 ° C). The resulting crystalline material is collected by suction filtration, washed with anhydrous ethanol, and dried in vacuo at 25 ° C. overnight (approximately 16 hours). This gives 16.9 g (85% pure crystalline monoethanolamine salt of N - (. 2-pyridyl) -2-methyl-4-OXY-2H-1, 2-benzothiazine-3-carboxamide 1,1-dioxide, named polymorph I, mp 179-180,5 ° C.
Melting point test, differential thermal analysis
(DTA), IR spectra in KBG and data
X-ray analysis confirmed the presence of a new polymorph. C, TH, j, N405S
Calculated: C 52.03; H 4.14; N 14.28
Found: C, 52.20; H 5.39, - N 14.31 ..
Example In a 125 ml single-neck round bottom flask,
equipped with a magnetic stirrer and a glass stopper, 10 g of the monoethanolamine salt of N- (2-pyridyl) -2 -2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide prepared in example 1 of polymorph II,
1.0 g of polymorph I and 100 ml of anhydrous ethanol. The resulting mixture is then stirred at ambient temperature for 74 hours. Then
the mixture is filtered and the target product is isolated by filtration under vacuum, and then it is dried under vacuum at 45 ° C until a constant current mass is obtained. So get 9.9 g
(90%) pure crystalline monoethanolamine salt of N- (2-pyridyl) -2 -2-methyl-4-hydroxy-2H-1,2 benzothiazine-3-carboxamide 1,1-dioxide in the form of polymorph I, -t.p . 178-180 ° C.
51D
Example 4 is carried out analogously to Example 3, except that isopropyl alcohol (100 ml) is used as the solvent instead of ethanol and stirred for 73.5 hours. Thus, 10.7 g (97 g) are obtained. %) pure crystalline monoethanolamine salt of H- (2-pyridyl) -2-methyl-4-scsi-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide in the form of polymorph I, m.p. . 178-180 ° C.
EXAMPLE 5 The procedure is carried out as in Example 3, except that acetonitrile (100 ml) is used as a solvent instead of ethanol and the mixture is stirred for 73.5 hours. Thus, 10.5 g are obtained ( 95%) of the pure crystalline monoethanolamine salt of N- (2- -pyridyl) -2-methyl-4-hydroxy-2H-1,2-benzothiaein-3-carboxamide 1,1-dioxide in the form of polymorph I, t. P. 178-180 ° C.
EXAMPLE 6) The ier is carried out according to Example 3, except that acetone (100 ml) is used as the solvent instead of eta-nola. Thus, 7.1 g (6A%) of the pure crystalline monoethanolamine salt of M- (2-pyridyl) -2 -2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide in polymorph I form, etc. 178-180 C.
Example 7. It is carried out as in Example 3, but methylene chloride (100 ml) is used as a solvent instead of ethanol and stirring is carried out for 73.3 hours. 10.1 g (92%) of pure crystalline are obtained in this way. monoethanolamine salt of N- (2-pyridyl) -2-ETHIL-4-OK-SI-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide in the form of polymorph I, so pl. 178-180 ° C.
Example8. In a 125-ml single-neck round-bottomed flask equipped with a magnetic stirrer and a glass stopper, 10 g of K- (2-pyridyl) -2-me-TYL-4-OXI-2H-1,2-benzothiazine-3-car monoethanol salt are placed. - boxamide 1,1-dioxide, obtained in example 1 (polymorph II), and 100 ml of methanol. The resulting mixture was stirred at ambient temperature for 70.7 hours (the solution was obtained after 5 minutes). The resulting crystalline material is then collected by suction filtration and then dried under vacuum at 45 ° C to
396
constant mass. Thus, 3.9 g (39%) of pure crystalline monoethanolamine salt of L- (2-pyridyl) -2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide is obtained. polymorph I form, etc. 178-180 ° C (like the starting material of polymorph II, 170-172 ° C while determining when heated with
speed of 1 ° per minute after 165 C). DTL and IR spectra in KBG confirm that the product obtained is absolutely identical to the product obtained in Example 1 (i.e. it is polymorph I).
Figure 1 shows the IR spectrum of the polymorph I form of the monoethanolamine salt of N- (2-pyridyl) -2-methyl-4-hydroxy--211-1,2-benzothiazine-2-carboxamide 1, 1-dioxide in KBr; FIG. 2 shows the IR spectrum of the polymorph II form of the monoethanolamine salt of N- (2-pyridyl) -2-methyl-4-OXY-2H, 1,2-benzothiazine-3-carboxamide 1,1-dioxide in KBr; FIG. 3 X-ray diffraction pattern of the polymorph I form of the monoethanolamine salt of N- (2-pyridyl) -2-methyl-4-hydroxy-2H-1,2-benzothiazine-4-carboxamide 1, 1-dioxide, in FIG. 4 - that however, the polymorph II of the monoethanolamine salt of N- (2-pyridyl) -2-me- TIL-4-OXI-2H is 1,2-benzothiazine-3-carboxamide 1,1-dioxide.
These spectra were obtained using a Perkin-Elmer model 21 spectrophotometer, which uses KBr tablets obtained by carefully grinding (in a mortar) 1.0 mg of the respective sample and 300 mg KBG. The mixture is then placed in the Perkin-Elmer press model, model 1860025, and is applied to the mold with a pressure of 1.055 kg / cm under vacuum for 1 minute.
The x-ray diffraction carfins shown in FIG. 3 and 4 were obtained on a diffractometer. Simens equipped with a copper-nickel emitter and a flicker detector. In this analysis method, the radiation intensity is recorded as a function of the angle 29 at a speed of 1 per minute.
As can be seen from the above examples and data of X-ray diffraction and IR spectral analyzes, the obtained new crystalline polymorph I melts at temperatures in the range e 178-180.5 ° C with decomposition and gives an x-ray diffraction pattern with characteristic peaks in degrees 29 at: 10.6 % 12.1 °, 13.0 ° 17.4% 17.6% 18.1% 19.3% 20.4 °, 21.1% 21.9 °, 22.8% 26.4 ° 28, 7% 29.0% 30.4% 31.9 ° and 32, (FIG. 3), IR surveys n KBr () give the spectrum: 1620, 1595, 1570, 1530, 1310, 1435, 1400, 1315, 1300, 1287, 1250, 1235, 1180, 1165, 1150, 1112, 1090, 1060, 1010, 990, 975, 930, 870, 800, 770, 775, 735, 660, 650, 620, 365, 340, 510, 455, 400 and 365.
In tab. Figure 1 shows the comparative data of IR analyzes of polymorph 1 and polymorph II (the most characteristic bands), which allow them to be distinguished from each other.
The form of polymorph I of the monoethanolamine salt of M- (2-pyridyl) -2-methyl-4-oxCI-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide is also easily distinguished from the form of polymorph II by X-ray diffractometry, the results of which are shown in Fig.Z and 4.
Peaks (in degrees 20) that can be used to distinguish polymorphic forms from one another,
are presented in table. 2
t
Another way by which polymorph I can be distinguished from polymorph II, the forms of the monoethanolamine salt of M- (2-pyridyl) -2-me-. : 1l-4-ox-SI-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, is a method that incorporates differential scanning calorimetry (DSC) - or differential thermal analysis (DTA) Samples (12 mg ) examined on a Meltler DTA 2000 analyzer in the range of 50-100 µV at a heating rate of 20 ° C per minute, the sample being introduced at 25 ° C. In tab. 3 shows the DSC data
The stability study was carried out on serial samples of the forms of polymorph I and polymorph II of the monoethanolamine salt of M- (2-pyridyl) -2-methyl-4-hydroxy-2H- -1,2-benzothiazine-3-carboxamide 1,1-dioxide. In these studies, samples were stored in clean glass vessels at 25 ° C, exposing them to sunlight, and at a temperature of 50 ° C in an oven. After storage under these conditions for 6 weeks and then another 12 weeks, samples were examined for visual or chemical changes. It was found that all samples had good chemical stability, but the stability of polymorph I significantly exceeded the stability of polymorph II. For example, polymorph I gave an intermediate impurity after 6 weeks of storage at 50 ° C, while polymorph II found such degradation after only a few days of storage at room temperature 1-1e, which was detected by high pressure liquid chromatography.
From the above comparison of the two polymorphic forms of the monoethanolamine salt 5, N- (2-pyridyl) -2-methyl-4-hydroxy-2H- -1,2-benzothiazine-3-carboxamide 1,1-dioxide, it is clear that the form polymorph I has significant advantages over the form of polymorph II, in that it is extremely stable under normally existing storage conditions, including exposure to solar radiation. In addition, this form can be easily obtained by the described methods.
A new form of polymorph I monoethanolamine salt K- (2-pyridinl) -2-me-TIL-4-OXI-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, obtained Q according to the present invention, can easily be adapted for therapeutic use as an anti-arteritis agent. For example, polymorph I of this salt exhibits anti-inflammatory activity in a standard test in rats. In this trial, the anti-inflammatory activity is defined as the percentage of slowing the formation of edema on the hind paw of an albino male male (weight 150-190 g) in response to the introduction of carrageenus into the sole. Carrageen is administered in the form of a 1% aqueous suspension (0.05 ml) 1 h after the oral administration of the preparation, which is usually given in the form of an aqueous solution. The formation of edema is determined by measuring the volume of the paw to which the injection was made, initially, as well as 3 hours after the injection of carrageen. The increase in volume 3 hours after administration of the carrageenum constitutes the individual response of the organism. It is believed that the drug is active under these conditions, if the difference
0
55
in response to the treated animals (six rats in the group) and in the control group in which only the vehicle was administered to animals, is significant when compared with the results obtained using standard compounds such as acetylsalicylic acid at a dose of 100 mg / kg or Phenylbutazone at a dose of 33 mg / kg, which was administered orally. At this, it was found that the obtained polymorphic form stops the swelling at a dose of 33 mg / kg by oral administration.
Polymorph I monoethanolamine A salt exhibits all the advantages of the previously obtained polymorph II, but is also more stable. For example, although K- (2-pyridyl) -2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide itself 1,1-dioxide (pyroxicam) is very poorly soluble in water, the polymorph I form of the monoethanol amine salt of L- (2-pyridyl) -2-me-TILE-A-OXY-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide is very readily dissolves in the specified solvent (i.e., it is soluble) and therefore enters the blood stream more quickly when taken orally than the corresponding less soluble calcium salt or even the anhydrous sodium salt of the indicated preparation. In addition, the obtained polymorphic form of monoethanolamine salt allows to obtain a pure aqueous solution prepared by the method even at a very high concentration level (more than 100 mg / mp). This contrasts significantly with the trimethylamine salt of N- (2-pyridyl) -2-methyl-4-ox-CI-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide and the corresponding tri-ethanolamine salt, which is a poor solution in water, and in an ammonium salt, which is very unstable when exposed to dry vacuum. In addition, the polymorphic salt obtained is a crystalline, non-hygroscopic solid which is easy to make in a very pure form. These specific properties and stability facilitate handling large volumes of this salt, packaging it in pharmaceutical doses, which is important for oral, topical, parenteral or rectal administration of this drug.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining the crystalline form of the monoethanolamine salt of N- (2-pyridin) -2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide polymorph I having a melting point of 178- 180.5 C with decomposition, X-ray diffraction analysis, giving a diffraction pattern with characteristic peaks, expressed in 20 degrees at 10.6 °, 12.1, 13.0 °, 17.4% 17.6 °, 18.1, 19 , 3 ;, 20.4 ° 21.1, 21.9, 22.8, 26.4, 28.7, 29.0 °, 30.4 °, 31.9 ° and 32.5 and the infrared spectrum in potassium bromide in 1620, 1595, 1570, 1530, 15tO, 1435, 1400, 1315, 1300, 1287, 1250, 1235, 1180, P65, 1150, 1112, 1090. 1060, 1010, 990, 975.930, 870, 800.770 755, 735, 660, 650, 620, 565, 540, 510, 455, 400 and 365, differing resulting from the fact that N-2-pyridyl (-2- -methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxide is reacted with monoethanolamine in an organic solvent to obtain a crystalline reaction product - polymorph II, followed by crystallization of the target polymorph I from a solution of the obtained polymorph II in a polar proton solvent selected from the group containing methanol, ethanol, isopropanol, or an aprotic solvent selected from the group containing acetonitrile, acetone, chloride methylene, with stirring in those ix 3,3-74 hours at 20-25 C until completion of the formation of polymorph I. I T a b l e 1
more intense
149131912
Continuation of table.1 II
Product Characteristic Bands
cm (U Grade
755 13.25
734 13.61 morph II 1250 8.00
1235 8.10 1233 cm strip is stronger
930 10.75 Doublet
775 12.90
765 13.07 765 cm the band is the most intense
7A5 13.42
Table 2 products Characteristic peaks, degrees 29
morph I 17.4 17.6 18.1 29.0 30.4 morph II 16.0 19.7 27.6 41.5
 - -- -- - .- - - - - - -,-- at.-- - ..."."
Table3
Product Type Summary DSC Data
samples
Polymorph I Endotherm at 190 ° C Polymorph II Endotherm at 177 ° C
i4.0 5.0 6.0
20
75RO 7000 1 00 1600 74/7/7 VOO 1000 100 600 tOO 300 FIG. 1 (.0 10
16 70 5
 20
2500 2000 1800 WOO 1200 WOO 800 600 tOO 200 FIG.
1520
25Jff
Fe / gz
16 20 2yo SO
35
15
20
25 JO of FIG. ft35

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP5086069B2|2012-11-28|Atazanavir bisulfate and process for producing novel forms

---

US4442101A|1984-04-10|Sesquihydrate of naphthyridine derivative, and process for the preparation thereof

---

JP2012236841A|2012-12-06|Crystal modification b of 8-cyano-1-cyclopropyl-7-|-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid

---

SU1491339A3|1989-06-30|Method of producing crystalline form of monoethanolamine salt of n-|-2-methyl-4-oxy-2n-1,2-benzothiazin-3-carboxamide

---

RU1796625C|1993-02-23|3-amino-7-nitro-4-|-2-phenyl-1| isoquinolone having analeptic effect

---

KR880001477B1|1988-08-13|Process for preparing niflumic acid morpholinoethyl ester diniflumate

---

US2906757A|1959-09-29|Their preparation

---

GB2098989A|1982-12-01|Lysine salts

---

KR19980064288A|1998-10-07|New Form of Polysiloxane Mesylate |

---

RU2248356C2|2005-03-20|8-cyano-1-cyclopropyl-7-|-6- flu oro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid of crystalline modification c and medicinal agent eliciting effect against pathogenic microorganisms

---

IE47009B1|1983-11-30|Improvements in or relating to benoxaprofen

---

US4851420A|1989-07-25|2,6-diamino-3-halobenzylpyridines and processes for their manufacture as well as their use in pharmaceuticals

---

US4087437A|1978-05-02|2-Phenyl-5-benzoxazolylalkanoic acid purification process

---

US4076715A|1978-02-28|13-Bromo lysergic acid compounds

---

DK152361B|1988-02-22|ANALOGY PROCEDURE FOR THE PREPARATION OF N- | -BENZAMIDES

---

US3959370A|1976-05-25|N-acetyl l-polychlorobenzamide compounds

---

SU1342899A1|1987-10-07|Method of producing 2-amino-2-methylpropanthiosulfuric acid

---

FI69454C|1986-02-10|SAETT ATT FRAMSTAELLA EN THERMODYNAMIC STABILIZED POLYMORF FORM OF THERAPEUTIC ANVAENDBAR 2- | -ALPHATE-METHYL-5-BENZOZAZOLYL ACETY

---

SU1089092A1|1984-04-30|Process for preparing 3-|-1 indole

---

US4486429A|1984-12-04|Amino derivatives of 4-phenyl 4-oxobuten-2-oic acid, pharmaceutical compositions containing them, and methods for preparing and therapeutically using them

---

EP0221032B1|1991-01-02|Sodium salt of etodolic acid and process for its preparation

---

SU1704631A3|1992-01-07|Method for preparation polymorphous form of famotidine

---

CN111094241A|2020-05-01|Crystal form of oxopyridine amide derivative and preparation method thereof

---

KR820000496B1|1982-04-08|Process for preparing quinazoline derivatives

---

KR840000890B1|1984-06-26|Process for preparing 5-position substituted 5,10-dihydro 11 h - dibenzo | diazepine - 11 - ones

同族专利:

---

公开号 | 公开日

---

ZA858773B|1987-06-24|

---

KR860004038A|1986-06-16|

---

PT81490B|1988-03-03|

---

FI854512A|1986-05-17|

---

US4582831A|1986-04-15|

---

CN85108245A|1986-09-03|

---

DD242405A5|1987-01-28|

---

KR870000291B1|1987-02-25|

---

NZ214201A|1988-07-28|

---

FI82045B|1990-09-28|

---

YU44019B|1990-02-28|

---

AU556378B2|1986-10-30|

---

EP0182572A1|1986-05-28|

---

HUT40116A|1986-11-28|

---

DK171726B1|1997-04-14|

---

MY101984A|1992-02-29|

---

NO854574L|1986-05-20|

---

DK527585A|1986-05-17|

---

JPH0425957B2|1992-05-06|

---

DE3575925D1|1990-03-15|

---

ES8701712A1|1986-12-01|

---

AU4995085A|1986-05-22|

---

ES548878A0|1986-12-01|

---

CA1209572A|1986-08-12|

---

PL149466B1|1990-02-28|

---

IE852852L|1986-05-16|

---

JPS61122284A|1986-06-10|

---

CN1004001B|1989-04-26|

---

IN164207B|1989-01-28|

---

IL77051A|1989-03-31|

---

FI82045C|1991-01-10|

---

PT81490A|1985-12-01|

---

YU178585A|1987-12-31|

---

PL256259A1|1986-10-07|

---

PH21322A|1987-09-28|

---

FI854512A0|1985-11-15|

---

EG17621A|1991-08-30|

---

HU197899B|1989-06-28|

---

EP0182572B1|1990-02-07|

---

IE58288B1|1993-08-25|

---

GR852772B|1986-03-14|

---

AT50257T|1990-02-15|

---

DK527585D0|1985-11-15|

---

IL77051D0|1986-04-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3591584A|1968-08-27|1971-07-06|Pfizer|Benzothiazine dioxides|

---

IN160683B|1981-06-01|1987-07-25|Pfizer|

---

US4434164A|1981-06-01|1984-02-28|Pfizer Inc.|Crystalline benzothiazine dioxide salts|

---

RO88420A|1983-04-25|1986-01-30|Pfizer Inc,Us|PROCEDURE FOR THE PREPARATION OF PIROXICAN BASIC BATCHES EMPTY ON PHARMACEUTICAL SUPPORTS|US5436241A|1994-01-14|1995-07-25|Bristol-Myers Squibb Company|Topical anti-inflammatory compositions containing piroxicam|

---

US20030068829A1|2001-06-25|2003-04-10|Symyx Technologies, Inc.|High throughput crystallographic screening of materials|

---

AR040083A1|2002-05-22|2005-03-16|Smithkline Beecham Corp|BIS-ACID COMPOUND 3 '- [ - [1--1,5-DIHIDRO-3-METHYL-5-OXO-4H-PIRAZOL-4-ILIDEN] HYDRAZINE ] -2'-HYDROXI- [1,1'-BIFENIL] -3-CARBOXILICO, PROCEDURE TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE TO PREPARE SUCH FARMAC COMPOSITION|

---

ECSP077628A|2007-05-03|2008-12-30|Smithkline Beechman Corp|NEW PHARMACEUTICAL COMPOSITION|

---

EP2434894B1|2009-05-29|2016-08-31|Novartis AG|Methods of administration of thrombopoietin agonist compounds|

---

JP5851990B2|2009-07-29|2016-02-03|ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ|PLK inhibitor salt|

---

GB0914287D0|2009-08-14|2009-09-30|Pci Biotech As|Compositions|

法律状态:
2007-09-20| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: MM4A Effective date: 20041116 |

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/672,028|US4582831A|1984-11-16|1984-11-16|Anti-inflammatory polymorphic monoethanolamine salt of N--2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor|

---